About GP-2250
GP-2250 is a highly selective yet broadly active cancer therapeutic with a unique mechanism of action that suppresses cancers by disrupting their energy metabolism, bringing about cancer cell death.
Differentiators
What Sets GP-2250 Apart?
Broad oncology applications.
GP-2250 is a tumor-type agnostic agent that delivers broad utility across cancer etiologies.
Cancer cell selective.
Because it targets the energy metabolism of cancer cells specifically, GP-2250 is highly tumor cell selective.
Robust data.
Early Phase 1 clinical data are encouraging and demonstrate excellent safety and tolerability of GP-2250, consistent with preclinical results.
Synergistic activity.
GP-2250 has demonstrated powerful synergies with several existing cancer treatments.
Truly unique MOA.
GP-2250 leverages a unique and proprietary mechanism of action.
Interested in learning more?
Mechanism of Action
Novel, proprietary, transformative.
The real power of GP-2250 is its novel and proprietary mechanism of action, which targets two primary mechanisms of cancer cell energy production, causing metabolic and oxidative stress. Here’s how it works.
Normal cells and cancer cells generate energy differently. GP-2250 takes advantage of that difference.
GP-2250 decreases GAPDH, the enzyme that controls aerobic glycolysis, a key process in cancer cells’ ability to produce metabolic energy.
At the same time, GP-2250 also decreases αKGDH, an enzyme that is critical in the TCA cycle, a second process cancer cells rely on to create energy.
Together, the reduction of these two vital enzymes causes a significant decrease in ATP, the cell’s energy carrier, resulting in an oxidative and metabolic energy crisis.
AMPK is activated and the transcription factor NFkB is inhibited, generating metabolic stress. Meanwhile, reactive oxygen species (ROS) increases, generating oxidative stress. This results in apoptosis.
In addition, GP-2250’s reduction of NFkB results in anti-inflammatory, anti-angiogenic, and immuno-permissive activity.
Watch Our Mechanism of Action Video.
Intellectual Property
Robust, multi-layered protection. Over 100 issued and 40 pending patents.
- Composition of Matter (NCE & Formulations) Granted US & EU (2033)
- Manufacturing Process (2035-2036)
- Method of Treatment (2037)
- Mechanism of Action (2040-2043)
- Additional Compounds & Uses (2031-2042)
Pipeline
Broad applicability, intentional focus.
While GP-2250 has demonstrated broad utility across indications and therapeutic uses in preclinical and Phase 1 clinical studies, including where inflammatory cytokine suppression could be of therapeutic value, Panavance is focusing the initial clinical trials on pancreatic cancer—a condition with clear unmet needs. In addition, GP-2250 is also being developed for the treatment of ovarian cancer in combination with leading anti-cancer agents based on promising preclinical data with notable effectiveness.